Your browser version may not work well with NCBI's Web applications. More information here...
1: Br J Cancer. 2007 Jan 15;96(1):16-20. Epub 2006 Dec 19.Click here to read Links

Targeting BRAF in thyroid cancer.

Espinosa AV, Porchia L, Ringel MD.

Divisions of Endocrinology and Oncology, Department of Medicine, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA.

Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.

PMID: 17179987 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Thyroid (Armour® Thyroid)

    Thyroid is a hormone produced by the body. When taken correctly, thyroid is used to treat the symptoms of hypothyroidism (a condition where the thyroid gland does not produce enough thyroid hormone). Symptoms of hypothyr...

  • Source: AHFS Consumer Medication Information

Recent Activity